.png)
Gout Therapeutics Market by Product Type and Disease Condition - Global Industry Analysis and Forecast to 2027
Published On : May 2022 Pages : 107 Category: Medical Devices Report Code : HC055
SEGMENTS & REGIONS:
- Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa
Industry Trend Analysis
The global gout therapeutics market is estimated to be around $8 billion by 2027. This market has witnessed tremendous growth in last few years due to preface of various regenerative drugs and escalated acceptance of these biologics for treatment. This can be attributed to their capability to generate potent anti-inflammatory action which speeds up treatment time. Furthermore, many other drugs are currently under clinical trials which are likely to be launched in coming years which will play an important role in the market growth. Rising incidence of gout due to changes in lifestyle, growing alcohol consumption, increasing obesity and ingestion of some specific medications will drive the growth of this market. However, binding regulations and patent expiry of leading drugs will slow down the growth of global market.
Product Outlook and Trend Analysis
Non-steroidal anti-inflammatory drugs (NSAIDs) dominates the global market because of superior level of penetration of drug, lower cost, easy availability, and ability to ease pain faster as compared to other available drugs for gout attacks. Urate lowering agents sector is expected to grow at most prominent rate during forecast period. Increasing adoption and innovation of new drugs is likely to enhance market growth. Colchicines occupies significant share in global market, due to their ability to slow down severe inflammatory response by blocking actions of neutrophils responsible for gout attacks. In 2009, FDA approved use of Colchicines for treating gout related fevers.
Regional Outlook and Trend Analysis
In 2017, the global market was dominated by North America, which can be attributed to various factors such as presence of local primary players, extensive use of gout therapies, and easily availability. U.S. dominated the regional market in 2017, followed by Canada. It is likely to sustain its leading position in the global market during the forecast period, owing to expected launch of new drugs and urate-lowering drugs. In Europe, France and Germany hold highest share for gout disease treatment drugs. Asia-Pacific is projected to witness highest growth rate due to rising incidence of gout disease, increased investments in research for the development of new and alternate therapies. Furthermore, increasing consumption of alcohol and cigarettes, changing life style, and increase in obesity rates is likely to improve growth of gout therapeutics market.
Competitive Insights
Numerous multinational as well as local players dominate the global market. Major players comprise GlaxoSmithKline plc; Merck& Co. Inc.; AstraZeneca plc; Teijin Pharma Ltd.; Novartis AG; Takeda Pharmaceutical Company Ltd.; Savient Pharmaceuticals; and Regeneron Pharmaceuticals. Development of new and innovative products, collaborations and strategic acquisitions are some of the strategies acquired by market players to have competitive advantage over their rivals.
Market Opportunities
Major players in market are shifting their focus towards more serious gout cases in order to meet unmet medical needs of drugs for effective treatments. NSAIDs and Colchicines are expected to attract large investment due to their increasing adoption and success rate in treating acute as well as chronic gout disease. Many players have collaborated for research and development to develop more efficient drug for the treatment of gout diseases. The market will be dominated by urate lowering agents that has ability to prevent gout disease by blocking genes responsible for gout disease. With FDA approval of Zurampic (in 2017) to reduce uric acid level in blood and other new drugs in clinical trials will bring in huge opportunities for key players in the market.
Gout therapeutic market is segmented as follows –
By Product Type:
- Colchicines
- Corticosteroids
- NSAIDs
- Urate-lowering Agents
By Disease Condition:
- Acute Gout
- Chronic Gout
By Region:
· North America
- U.S
- Canada
- Mexico
· Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
· Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
· Rest of the World
- Brazil
- South Africa
- Saudi Arabia
- Turkey
- United Arab Emirates
- Others
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2022 to 2027?
- What will be the industry market growth from 2022 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
- Gout Therapeutic Market, By Product Type, Estimates and Forecast, 2017-2027 ($Million)
- NSAIDs Solid Scaffolds
- Corticosteroids
- Colchicines
- Urate-lowering Agents
- Gout Therapeutic Market, By Disease Condition, Estimates and Forecast, 2017-2027 ($Million)
- Chronic Gout
- Acute Gout
- Gout Therapeutic Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
- North America
- North America Gout Therapeutic Market, By Country
- North America Gout Therapeutic Market, By Product Type
- North America Gout Therapeutic Market, By Disease Condition
- U.S. Gout Therapeutic Market, By Product Type
- U.S. Gout Therapeutic Market, By Disease Condition
- Canada Gout Therapeutic Market, By Product Type
- Canada Gout Therapeutic Market, By Disease Condition
- Mexico Gout Therapeutic Market, By Product Type
- Mexico Gout Therapeutic Market, By Disease Condition
-
- Europe
- Europe Gout Therapeutic Market, By Country
- Europe Gout Therapeutic Market, By Product Type
- Europe Gout Therapeutic Market, By Disease Condition
- Germany Gout Therapeutic Market, By Product Type
- Germany Gout Therapeutic Market, By Disease Condition
- France Gout Therapeutic Market, By Product Type
- France Gout Therapeutic Market, By Disease Condition
- UK Gout Therapeutic Market, By Product Type
- UK Gout Therapeutic Market, By Disease Condition
- Italy Gout Therapeutic Market, By Product Type
- Italy Gout Therapeutic Market, By Disease Condition
- Spain Gout Therapeutic Market, By Product Type
- Spain Gout Therapeutic Market, By Disease Condition
- Rest of Europe Gout Therapeutic Market, By Product Type
- Rest of Europe Gout Therapeutic Market, By Disease Condition
-
- Asia-Pacific
- Asia-Pacific Gout Therapeutic Market, By Country
- Asia-Pacific Gout Therapeutic Market, By Product Type
- Asia-Pacific Gout Therapeutic Market, By Disease Condition
- Japan Gout Therapeutic Market, By Product Type
- Japan Gout Therapeutic Market, By Disease Condition
- China Gout Therapeutic Market, By Product Type
- China Gout Therapeutic Market, By Disease Condition
- Australia Gout Therapeutic Market, By Product Type
- Australia Gout Therapeutic Market, By Disease Condition
- India Gout Therapeutic Market, By Product Type
- India Gout Therapeutic Market, By Disease Condition
- South Korea Gout Therapeutic Market, By Product Type
- South Korea Gout Therapeutic Market, By Disease Condition
- Rest of Asia-Pacific Gout Therapeutic Market, By Product Type
- Rest of Asia-Pacific Gout Therapeutic Market, By Disease Condition
- Asia-Pacific
-
- Rest of the World
- Rest of the World Gout Therapeutic Market, By Country
- Rest of the World Gout Therapeutic Market, By Product Type
- Rest of the World Gout Therapeutic Market, By Disease Condition
- Brazil Gout Therapeutic Market, By Product Type
- Brazil Gout Therapeutic Market, By Disease Condition
- South Africa Gout Therapeutic Market, By Product Type
- South Africa Gout Therapeutic Market, By Disease Condition
- Saudi Arabia Gout Therapeutic Market, By Product Type
- Saudi Arabia Gout Therapeutic Market, By Disease Condition
- Turkey Gout Therapeutic Market, By Product Type
- Turkey Gout Therapeutic Market, By Disease Condition
- United Arab Emirates Gout Therapeutic Market, By Product Type
- United Arab Emirates Gout Therapeutic Market, By Disease Condition
- Others Gout Therapeutic Market, By Product Type
- Others Gout Therapeutic Market, By Disease Condition
- Rest of the World
Table of Contents
1. Introduction
1.1. Report Description
1.2. Research Methodology
1.2.1. Secondary Research
1.2.2. Primary Research
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Share Analysis
3.3. Market Dynamics
3.3.1. Drivers
3.3.1.1. Rising incidences of gout disease
3.3.1.2. Increase alcohol consumption
3.3.1.3. Rise in obesity
3.3.1.4. Consumption of other medication
3.3.2. Restraints
3.3.2.1. Binding regulations
3.3.2.2. Patent expiry of leading drugs
3.3.3. Opportunities
3.3.3.1. Emerging market to offer lucrative growth opportunities
3.4. Industry Trends
4. Gout Therapeutics Market, By Product Type
4.1. Introduction
4.2. Gout Therapeutics MarketAssessment and Forecast, By Product Type, 2017-2027
4.3. NSAIDs
4.3.1. Market Assessment and Forecast, By Region, 2017-2027 ($Million)
4.4. Corticosteroids
4.4.1. Market Assessment and Forecast, By Region, 2017-2027 ($Million)
4.5. Colchicine
4.5.1. Market Assessment and Forecast, By Region, 2017-2027 ($Million)
4.6. Urate-lowering agents
4.6.1. Market Assessment and Forecast, By Region, 2017-2027 ($Million)
5. Gout Therapeutics Market, By Disease Condition
5.1. Introduction
5.2. Gout Therapeutics MarketAssessment and Forecast, By Disease Condition,2017-2027
5.3. Chronic Gout
5.3.1. Market Assessment and Forecast, By Region, 2017-2027 ($Million)
5.3.2. Acute Gout
5.3.2.1. Market Assessment and Forecast, By Region, 2017-2027 ($Million)
6. Gout Therapeutics Market, By Region
6.1. Introduction
6.2. Gout Therapeutics MarketAssessment and Forecast, By Region, 2017-2027 ($Million)
6.3. North America
6.3.1. Market Assessment and Forecast, By Country, 2017-2027 ($Million)
6.3.2. Market Assessment and Forecast, By Product Type, 2017-2027 ($Million)
6.3.3. Market Assessment and Forecast, By Disease Condition, 2017-2027 ($Million)
6.3.3.1. U.S.
6.3.3.1.1. Market Assessment and Forecast, By Product Type, 2017-2027 ($Million)
6.3.3.1.2. Market Assessment and Forecast, By Disease Condition, 2017-2027 ($Million)
6.3.3.2. Canada
6.3.3.2.1. Market Assessment and Forecast, By Product Type, 2017-2027 ($Million)
6.3.3.2.2. Market Assessment and Forecast, By Disease Condition, 2017-2027 ($Million)
6.3.3.3. Mexico
6.3.3.3.1. Market Assessment and Forecast, By Product Type, 2017-2027 ($Million)
6.3.3.3.2. Market Assessment and Forecast, By Disease Condition, 2017-2027 ($Million)
6.4. Europe
6.4.1. Market Assessment and Forecast, By Country, 2017-2027 ($Million)
6.4.2. Market Assessment and Forecast, By Product Type, 2017-2027 ($Million)
6.4.3. Market Assessment and Forecast, By Disease Condition, 2017-2027 ($Million)
6.4.3.1. Germany
6.4.3.1.1. Market Assessment and Forecast, By Product Type, 2017-2027 ($Million)
6.4.3.1.2. Market Assessment and Forecast, By Disease Condition, 2017-2027 ($Million)
6.4.3.2. France
6.4.3.2.1. Market Assessment and Forecast, By Product Type, 2017-2027 ($Million)
6.4.3.2.2. Market Assessment and Forecast, By Disease Condition, 2017-2027 ($Million)
6.4.3.3. UK
6.4.3.3.1. Market Assessment and Forecast, By Product Type, 2017-2027 ($Million)
6.4.3.3.2. Market Assessment and Forecast, By Disease Condition, 2017-2027 ($Million)
6.4.3.4. Italy
6.4.3.4.1. Market Assessment and Forecast, By Product Type, 2017-2027 ($Million)
6.4.3.4.2. Market Assessment and Forecast, By Disease Condition, 2017-2027 ($Million)
6.4.3.5. Spain
6.4.3.5.1. Market Assessment and Forecast, By Product Type, 2017-2027 ($Million)
6.4.3.5.2. Market Assessment and Forecast, By Disease Condition, 2017-2027 ($Million)
6.4.3.6. Russia
6.4.3.6.1. Market Assessment and Forecast, By Product Type, 2017-2027 ($Million)
6.4.3.6.2. Market Assessment and Forecast, By Disease Condition, 2017-2027 ($Million)
6.4.3.7. Rest of Europe
6.4.3.7.1. Market Assessment and Forecast, By Product Type, 2017-2027 ($Million)
6.4.3.7.2. Market Assessment and Forecast, By Disease Condition, 2017-2027 ($Million)
6.5. Asia-Pacific
6.5.1. Market Assessment and Forecast, By Country, 2017-2027 ($Million)
6.5.2. Market Assessment and Forecast, By Product Type, 2017-2027 ($Million)
6.5.3. Market Assessment and Forecast, By Disease Condition, 2017-2027 ($Million)
6.5.3.1. Japan
6.5.3.1.1. Market Assessment and Forecast, By Product Type, 2017-2027 ($Million)
6.5.3.1.2. Market Assessment and Forecast, By Disease Condition, 2017-2027 ($Million)
6.5.3.2. China
6.5.3.2.1. Market Assessment and Forecast, By Product Type, 2017-2027 ($Million)
6.5.3.2.2. Market Assessment and Forecast, By Disease Condition, 2017-2027 ($Million)
6.5.3.3. Australia
6.5.3.3.1. Market Assessment and Forecast, By Product Type, 2017-2027 ($Million)
6.5.3.3.2. Market Assessment and Forecast, By Disease Condition, 2017-2027 ($Million)
6.5.3.4. India
6.5.3.4.1. Market Assessment and Forecast, By Product Type, 2017-2027 ($Million)
6.5.3.4.2. Market Assessment and Forecast, By Disease Condition, 2017-2027 ($Million)
6.5.3.5. South Korea
6.5.3.5.1. Market Assessment and Forecast, By Product Type, 2017-2027 ($Million)
6.5.3.5.2. Market Assessment and Forecast, By Disease Condition, 2017-2027 ($Million)
6.5.3.6. Taiwan
6.5.3.6.1. Market Assessment and Forecast, By Product Type, 2017-2027 ($Million)
6.5.3.6.2. Market Assessment and Forecast, By Disease Condition, 2017-2027 ($Million)
6.5.3.7. Rest of Asia-Pacific
6.5.3.7.1. Market Assessment and Forecast, By Product Type, 2017-2027 ($Million)
6.5.3.7.2. Market Assessment and Forecast, By Disease Condition, 2017-2027 ($Million)
6.6. Rest of the World
6.6.1. Market Assessment and Forecast, By Country, 2017-2027 ($Million)
6.6.2. Market Assessment and Forecast, By Product Type, 2017-2027 ($Million)
6.6.3. Market Assessment and Forecast, By Disease Condition, 2017-2027 ($Million)
6.6.3.1. Brazil
6.6.3.1.1. Market Assessment and Forecast, By Product Type, 2017-2027 ($Million)
6.6.3.1.2. Market Assessment and Forecast, By Disease Condition, 2017-2027 ($Million)
6.6.3.2. Turkey
6.6.3.2.1. Market Assessment and Forecast, By Product Type, 2017-2027 ($Million)
6.6.3.2.2. Market Assessment and Forecast, By Disease Condition, 2017-2027 ($Million)
6.6.3.3. Saudi Arabia
6.6.3.3.1. Market Assessment and Forecast, By Product Type, 2017-2027 ($Million)
6.6.3.3.2. Market Assessment and Forecast, By Disease Condition, 2017-2027 ($Million)
6.6.3.4. South Africa
6.6.3.4.1. Market Assessment and Forecast, By Product Type, 2017-2027 ($Million)
6.6.3.4.2. Market Assessment and Forecast, By Disease Condition, 2017-2027 ($Million)
6.6.3.4.3. Market Assessment and Forecast, By End Users, 2017-2027 ($Million)
6.6.3.5. United Arab Emirates
6.6.3.5.1. Market Assessment and Forecast, By Product Type, 2017-2027 ($Million)
6.6.3.5.2. Market Assessment and Forecast, By Disease Condition, 2017-2027 ($Million)
6.6.3.6. Others
6.6.3.6.1. Market Assessment and Forecast, By Product Type, 2017-2027 ($Million)
6.6.3.6.2. Market Assessment and Forecast, By Disease Condition, 2017-2027 ($Million)
7. Company Profiles
7.1. Takeda Pharmaceutical Company Ltd.
7.1.1. Business Overview
7.1.2. Product Portfolio
7.1.3. Key Financials
7.1.4. Strategic Developments
7.2. Novartis
7.2.1. Business Overview
7.2.2. Product Portfolio
7.2.3. Key Financials
7.2.4. Strategic Developments
7.3. Savient Pharmaceuticals
7.3.1. Business Overview
7.3.2. Product Portfolio
7.3.3. Key Financials
7.3.4. Strategic Developments
7.4. Regeneron Pharmaceuticals
7.4.1. Business Overview
7.4.2. Product Portfolio
7.4.3. Key Financials
7.4.4. Strategic Developments
7.5. AstraZeneca plc
7.5.1. Business Overview
7.5.2. Product Portfolio
7.5.3. Key Financials
7.5.4. Strategic Developments
7.6. Horizon Pharma plc
7.6.1. Business Overview
7.6.2. Product Portfolio
7.6.3. Key Financials
7.6.4. Strategic Developments
7.7. BoehringerIngelheim
7.7.1. Business Overview
7.7.2. Product Portfolio
7.7.3. Key Financials
7.7.4. Strategic Developments
7.8. Merck & Co. Inc
7.8.1. Business Overview
7.8.2. Product Portfolio
7.8.3. Key Financials
7.8.4. Strategic Developments
7.9. Teijin Pharma Ltd
7.9.1. Business Overview
7.9.2. Product Portfolio
7.9.3. Key Financials
7.9.4. Strategic Developments
7.10. GlaxoSmithKline plc
7.10.1. Business Overview
7.10.2. Product Portfolio
7.10.3. Key Financials
7.10.4. Strategic Developments
List of Tables
Table 1.Global Gout Therapeutics Market, By Product Type ($Million), 2017-2025
Table 3.NSAIDs Market, By Region ($Million), 2017-2025
Table 4.Corticosteroids Market, By Region ($Million), 2017-2025
Table 5.Colchicines Market, By Region ($Million), 2017-2025
Table 6.Urate-lowering Agents Market, By Region ($Million), 2017-2025
Table 10.Global Gout Therapeutics Market, By Disease Condition ($Million), 2017-2025
Table 11.Chronic Gout Market, By Region ($Million), 2017-2025
Table 12.Acute Gout Market, By Region ($Million), 2017-2025
Table 15.NorthAmerica Gout Therapeutics Market, By Country, 2017-2025 ($Million)
Table 16.North America Gout Therapeutics Market, By Product Type, 2017-2025 ($Million)
Table 16.North America Gout Therapeutics Market, By Disease Condition, 2017-2025 ($Million)
Table 17.U.S. Gout Therapeutics Market, By Product Type, 2017-2025 ($Million)
Table 17.U.S. Gout Therapeutics Market, By Disease Condition, 2017-2025 ($Million)
Table 18.Canada Gout Therapeutics Market, By Product Type, 2017-2025 ($Million)
Table 18.Canada Gout Therapeutics Market, By Disease Condition, 2017-2025 ($Million)
Table 19.Mexico Gout Therapeutics Market, By Product Type, 2017-2025 ($Million)
Table 19.Mexico Gout Therapeutics Market, By Disease Condition, 2017-2025 ($Million)
Table 20.Europe Gout Therapeutics Market, By Country, 2017-2025 ($Million)
Table 21.Europe Gout Therapeutics Market, By Product Type, 2017-2025 ($Million)
Table 21.Europe Gout Therapeutics Market, By Disease Condition, 2017-2025 ($Million)
Table 22.Germany Gout Therapeutics Market, By Product Type, 2017-2025 ($Million)
Table 22.Germany Gout Therapeutics Market, By Disease Condition, 2017-2025 ($Million)
Table 23.France Gout Therapeutics Market, By Product Type, 2017-2025 ($Million)
Table 23.France Gout Therapeutics Market, By Disease Condition, 2017-2025 ($Million)
Table 24.UK Gout Therapeutics Market, By Product Type, 2017-2025 ($Million)
Table 24.UK Gout Therapeutics Market, By Disease Condition, 2017-2025 ($Million)
Table 25.Italy Gout Therapeutics Market, By Product Type, 2017-2025 ($Million)
Table 25.Italy Gout Therapeutics Market, By Disease Condition, 2017-2025 ($Million)
Table 26.Spain Gout Therapeutics Market, By Product Type, 2017-2025 ($Million)
Table 26.Spain Gout Therapeutics Market, By Disease Condition, 2017-2025 ($Million)
Table 27.Russia Gout Therapeutics Market, By Product Type, 2017-2025 ($Million)
Table 27.Russia Gout Therapeutics Market, By Disease Condition, 2017-2025 ($Million)
Table 28.Rest of Europe Gout Therapeutics Market, By Product Type, 2017-2025 ($Million)
Table 28.Rest of Europe Gout Therapeutics Market, By Disease Condition, 2017-2025 ($Million)
Table 29.Asia-Pacific Diabetes Devices Market, By Country, 2017-2025 ($Million)
Table 30.Asia-Pacific Gout Therapeutics Market, By Product Type, 2017-2025 ($Million)
Table 30.Asia-Pacific Gout Therapeutics Market, By Disease Condition, 2017-2025 ($Million)
Table 31.Japan Gout Therapeutics Market, By Product Type, 2017-2025 ($Million)
Table 31.Japan Gout Therapeutics Market, By Disease Condition, 2017-2025 ($Million)
Table 32.China Gout Therapeutics Market, By Product Type, 2017-2025 ($Million)
Table 32.China Gout Therapeutics Market, By Disease Condition, 2017-2025 ($Million)
Table 33.Australia Gout Therapeutics Market, By Product Type, 2017-2025 ($Million)
Table 33.Australia Gout Therapeutics Market, By Disease Condition, 2017-2025 ($Million)
Table 34.India Gout Therapeutics Market, By Product Type, 2017-2025 ($Million)
Table 34.India Gout Therapeutics Market, By Disease Condition, 2017-2025 ($Million)
Table 35.South Korea Gout Therapeutics Market, By Product Type, 2017-2025 ($Million)
Table 35.South Korea Gout Therapeutics Market, By Disease Condition, 2017-2025 ($Million)
Table 36.Taiwan Gout Therapeutics Market, By Product Type, 2017-2025 ($Million)
Table 35.Taiwan Gout Therapeutics Market, By Disease Condition, 2017-2025 ($Million)
Table 37.Rest of Asia-Pacific Gout Therapeutics Market, By Product Type, 2017-2025 ($Million)
Table 35.Rest of Asia-Pacific Gout Therapeutics Market, By Disease Condition, 2017-2025 ($Million)
Table 38.Rest of the World Gout Therapeutics Market, By Country, 2017-2025 ($Million)
Table 30.Rest of the World Gout Therapeutics Market, By Product Type, 2017-2025 ($Million)
Table 30.Rest of the World Gout Therapeutics Market, By Disease Condition, 2017-2025 ($Million)
Table 40.Brazil Gout Therapeutics Market, By Product Type, 2017-2025 ($Million)
Table 35.Brazil Gout Therapeutics Market, By Disease Condition, 2017-2025 ($Million)
Table 41.Turkey Gout Therapeutics Market, By Product Type, 2017-2025 ($Million)
Table 41.Turkey Gout Therapeutics Market, By Disease Condition, 2017-2025 ($Million)
Table 42.Saudi Arabia Gout Therapeutics Market, By Product Type, 2017-2025 ($Million)
Table 42.Saudi Arabia Gout Therapeutics Market, By Disease Condition, 2017-2025 ($Million)
Table 43.South Africa Gout Therapeutics Market, By Product Type, 2017-2025 ($Million)
Table 43.South Africa Gout Therapeutics Market, By Disease Condition, 2017-2025 ($Million)
Table 44.United Arab Emirates Gout Therapeutics Market, By Product Type, 2017-2025 ($Million)
Table 44.United Arab Emirates Gout Therapeutics Market, By Disease Condition, 2017-2025 ($Million)
Table 45.Others Gout Therapeutics Market, By Product Type, 2017-2025 ($Million)
Table 44.Others Gout Therapeutics Market, By Disease Condition, 2017-2025 ($Million)
Table 46.Takeda Pharmaceutical Company Ltd.: Key Strategic Developments, 2017-2017
Table 47.Novartis: Key Strategic Developments, 2017-2017
Table 48.Becton, Dickinson and Company: Key Strategic Developments, 2017-2017
Table 49.Savient Pharmaceuticals: Key Strategic Developments, 2017-2017
Table 50.Regeneron Pharmaceuticals: Key Strategic Developments, 2017-2017
Table 51.AstraZeneca plc: Key Strategic Developments, 2017-2017
Table 52.Horizon Pharma plc: Key Strategic Developments, 2017-2017
Table 53.Boehringer Ingelheim: Key Strategic Developments, 2017-2017
Table 54.Teijin Pharma Ltd: Key Strategic Developments, 2017-2017
Table 55.GlaxoSmithKline plc: Key Strategic Developments, 2017-2017
List of Figures
Figure 1.Global Gout Therapeutics Market Share, By Product Type, 2017 & 2025
Figure 2.Gout Therapeutics Market Share, By Disease Condition, 2017 & 2025
Figure 3.Gout Therapeutics Market, By Region, 2017, ($Million)
Figure 4.Takeda Pharmaceutical Company Ltd.: Net Revenues, 2017-2017 ($Million)
Figure 5.Takeda Pharmaceutical Company Ltd.: Net Revenue Share, By Segment, 2017
Figure 6.Takeda Pharmaceutical Company Ltd.: Net Revenue Share, By Geography, 2017
Figure 7.Novartis: Net Revenues, 2017-2017 ($Million)
Figure 8.Novartis: Net Revenue Share, By Segment, 2017
Figure 9.Novartis: Net Revenue Share, By Geography, 2017
Figure 10.Savient Pharmaceuticals: Net Revenues, 2017-2017 ($Million)
Figure 11.Savient Pharmaceuticals: Net Revenue Share, By Segment, 2017
Figure 12.Savient Pharmaceuticals: Net Revenue Share, By Geography, 2017
Figure 13.Regeneron Pharmaceuticals: Net Revenues, 2017-2017 ($Million)
Figure 14.Regeneron Pharmaceuticals: Net Revenue Share, By Segment, 2017
Figure15.Regeneron Pharmaceuticals: Net Revenue Share, By Geography, 2017
Figure16.AstraZeneca plc: Net Revenues, 2017-2017 ($Million)
Figure 17.AstraZeneca plc: Net Revenue Share, By Segment, 2017
Figure18.AstraZeneca plc: Net Revenue Share, By Geography, 2017
Figure19.Horizon Pharma plc: Net Revenues, 2017-2017 ($Million)
Figure 20.Horizon Pharma plc: Net Revenue Share, By Segment, 2017
Figure 21.Horizon Pharma plc: Net Revenue Share, By Geography, 2017
Figure 22.Boehringer Ingelheim: Net Revenues, 2017-2017 ($Million)
Figure 23.Boehringer Ingelheim: Net Revenue Share, By Segment, 2017
Figure 24.Boehringer Ingelheim: Net Revenue Share, By Geography, 2017
Figure 25.Merck & Co. Inc: Net Revenues, 2017-2017 ($Million)
Figure 26.Merck & Co. Inc: Net Revenue Share, By Segment, 2017
Figure27. Merck & Co. Inc: Net Revenue Share, By Geography, 2017
Figure 28.Tandem Diabetes Care, Inc: Net Revenues, 2017-2017 ($Million)
Figure 29.Tandem Diabetes Care, Inc: Net Revenue Share, By Segment, 2017
Figure 30.Tandem Diabetes Care, Inc: Net Revenue Share, By Geography, 2017
Figure 31Teijin Pharma Ltd: Net Revenues, 2017-2017 ($Million)
Figure 32.Teijin Pharma Ltd: Net Revenue Share, By Segment, 2017
Figure33.Teijin Pharma Ltd: Net Revenue Share, By Geography, 2017
Figure 34.GlaxoSmithKline plc: Net Revenues, 2017-2017 ($Million)
Figure 35.GlaxoSmithKline plc: Net Revenue Share, By Segment, 2017
Figure 36.GlaxoSmithKline plc: Net Revenue Share, By Geography, 2017
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|